-Outlook As the India and the EU negotiate a Free Trade agreement, a Parliamentary panel today cautioned against its early signing and asked Prime Minister Manmohan Singh to wait for the committee's report before finalising it. Chairman of the Department Related Parliamentary Committee on Commerce Shanta Kumar has written to Prime Minister today asking him not to rush through the EU-India Broad based Trade and Investment Agreement (BTIA) before the panel gives...

-The Economic Times The recent patent rulings in India may get frequently challenged in international courts if the government yields to the European Union's demand of including matters related to intellectual property in the investors-state dispute mechanism in their proposed trade pact, health activist groups have warned. An investor-state dispute resolution mechanism typically allows foreign investors to sue countries for compensation if national laws, policies, court rulings of the country infringe upon...

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

-Outlook India has long been the sleeping giant of global agriculture. But its misguided policies while boosting short-term output, yet may transform India into a food importer After decades on the sidelines of international agricultural trade, India was poised last year to become a major food supplier, overtaking traditional exporters of food grain and meat. This could prove to be flash in the pan. The sudden rise and fall of India...

-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...